Published in Blood on July 15, 2002
Graft-versus-host disease. Lancet (2009) 8.78
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant (2014) 2.46
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood (2013) 1.94
Current issues in chronic graft-versus-host disease. Blood (2014) 1.83
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood (2005) 1.73
Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant (2011) 1.66
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res (2014) 1.58
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56
Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. Blood (2012) 1.48
Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant (2012) 1.46
Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model. J Invest Dermatol (2015) 1.39
Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica (2011) 1.32
Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant (2008) 1.32
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia (2011) 1.26
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol (2010) 1.24
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2014) 1.23
New approaches for preventing and treating chronic graft-versus-host disease. Blood (2005) 1.20
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood (2005) 1.18
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant (2015) 1.12
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica (2011) 1.10
Aberrant B-cell homeostasis in chronic GVHD. Blood (2015) 1.06
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood (2011) 1.05
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant (2014) 0.98
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant (2009) 0.97
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood (2016) 0.96
Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 0.95
Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am (2010) 0.94
Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol (2013) 0.93
The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. Dtsch Arztebl Int (2011) 0.92
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant (2008) 0.89
Providing personalized prognostic information for adult leukemia survivors. Biol Blood Marrow Transplant (2013) 0.89
Gynecologic complication of chronic graft-versus-host disease: Vaginal obstruction. Obstet Gynecol Sci (2013) 0.89
Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol (2010) 0.87
Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia (2015) 0.87
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant (2013) 0.86
The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol (2011) 0.86
Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transplant (2013) 0.86
Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant (2013) 0.86
Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica (2014) 0.85
Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol (2014) 0.85
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia (2012) 0.85
Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant (2012) 0.84
Incorporating short-term outcome information to predict long-term survival with discrete markers. Biom J (2011) 0.84
Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 0.84
A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials. Rev Bras Hematol Hemoter (2011) 0.83
Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. Transfusion (2014) 0.83
Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol (2016) 0.83
Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica (2012) 0.82
Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. Biol Blood Marrow Transplant (2015) 0.80
Characterization of long-term mixed donor-donor chimerism after double cord blood transplantation. Clin Exp Immunol (2010) 0.80
Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantation. J Support Oncol (2010) 0.79
Grading criteria for chronic ocular graft-versus-host disease: comparing the NIH eye score, Japanese dry eye score, and DEWS 2007 score. Sci Rep (2014) 0.79
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am J Hematol (2013) 0.79
Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis. Bone Marrow Transplant (2015) 0.78
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant (2014) 0.78
Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. Br J Haematol (2015) 0.77
Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling. Stem Cells Dev (2015) 0.77
Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol (2013) 0.77
How closely related is graft-vs-leukemia to donor/recipient disparity? Best Pract Res Clin Haematol (2010) 0.76
Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. Bone Marrow Transplant (2015) 0.76
Immune Reactions following Cord Blood Transplantations in Adults. Stem Cells Int (2011) 0.76
Landmark risk prediction of residual life for breast cancer survival. Stat Med (2013) 0.76
Landmark Prediction of Long Term Survival Incorporating Short Term Event Time Information. J Am Stat Assoc (2012) 0.76
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Korean J Intern Med (2016) 0.76
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol (2016) 0.76
Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome. Indian J Hematol Blood Transfus (2015) 0.75
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.75
Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant (2014) 0.75
Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study. PLoS One (2016) 0.75
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen. Med Sci Monit (2011) 0.75
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses (2016) 0.75
High incidence of severe chronic GvHD after HSCT with sibling donors. A single center analysis. Bone Marrow Transplant (2016) 0.75
Ex Vivo CD34+ Selected T-Cell Depleted (TCD) Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Treatment Response. Biol Blood Marrow Transplant (2016) 0.75
Pathophysiology of GvHD and Other HSCT-Related Major Complications. Front Immunol (2017) 0.75
Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. J Oncol Pharm Pract (2015) 0.75
Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children. Bone Marrow Transplant (2014) 0.75
Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation. Int J Hematol Oncol Stem Cell Res (2015) 0.75
Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD. Bone Marrow Transplant (2016) 0.75
Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. Bone Marrow Transplant (2016) 0.75
Immunotherapy for acute leukemia. Aging (Albany NY) (2015) 0.75
Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. PLoS One (2017) 0.75
Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. J Immunol (2017) 0.75
Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation. Eur Radiol (2014) 0.75
Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI. J Cancer Res Clin Oncol (2014) 0.75
Evolving concepts in prognostic scoring of chronic GvHD. Bone Marrow Transplant (2017) 0.75
Graft-versus-host disease: A rare complication of device implantation. HeartRhythm Case Rep (2016) 0.75
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 7.10
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet (2007) 6.93
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant (2009) 6.22
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 4.02
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 3.62
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood (2003) 3.42
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant (2002) 3.29
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2008) 3.18
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol (2010) 2.99
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Acute Myeloid Leukemia. N Engl J Med (2015) 2.85
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood (2010) 2.73
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol (2012) 2.68
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 2.65
A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed (2007) 2.60
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant (2007) 2.60
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood (2007) 2.54
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol (2011) 2.49
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg (2011) 2.43
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 2.41
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal (2004) 2.37
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35